Anti-Parkinson Drugs and Orexin Neurons

Vitamins and Hormones

Volumn 89, Issue , 2012, Pages 279-290

  Katsuki, Hiroshi ^a   Michinaga, Shotaro ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b OSAKA OHTANI UNIVERSITY   (Japan)

Author keywords

Dopamine receptor; Hypocretin; Narcolepsy; Neurodegenerative disorder; Neuropeptide turnover; Parkinson disease

Indexed keywords

EID: 84861471573     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394623-2.00015-9     Document Type: Chapter

References (37)

1. Acuna-Goycolea C., Li Y., van den Pol A.N. Group III metabotropic glutamate receptors maintain tonic inhibition of excitatory synaptic input to hypocretin/orexin neurons. J. Neurosci. 2004, 24:3013-3022.
2. Alberto C.O., Trask R.B., Quinlan M.E., Hirasawa M. Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. J. Neurosci. 2006, 26:10043-10050.
3. Arnulf I., Leu-Semenescu S. Sleepiness in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:S101-S104.
4. Asai H., Hirano M., Furiya Y., Udaka F., Morikawa M., Kanbayashi T., Shimizu T., Ueno S. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Clin. Neurol. Neurosurg. 2009, 111:341-344.
5. Aziz A., Fronczek R., Maat-Schieman M., Unmehopa U., Roelandse F., Overeem S., van Duinen S., Lammers G.J., Swaab D., Roos R. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 2008, 18:474-483.
6. Bubser M., Fadel J.R., Jackson L.L., Meador-Woodruff J.H., Jing D., Deutch A.Y. Dopaminergic regulation of orexin neurons. Eur. J. Neurosci. 2005, 21:2993-3001.
7. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999, 98:437-451.
8. Drouot X., Moutereau S., Nguyen J.P., Lefaucheur J.P., Créange A., Remy P., Goldenberg F., d'Ortho M.P. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003, 61:540-543.
9. Foley P., Gerlach M., Double K.L., Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm. 2004, 111:1375-1446.
10. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
11. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
12. Hobson D.E., Pourcher E., Martin W.R. Ropinirole and pramipexole, the new agonists. Can. J. Neurol. Sci. 1999, 26:S27-S33.
13. Horvath J., Fross R.D., Kleiner-Fisman G., Lerch R., Stalder H., Liaudat S., Raskoff W.J., Flachsbart K.D., Rakowski H., Pache J.C., Burkhard P.R., Lang A.E. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov. Disord. 2004, 19:611-613.
14. Katsuki H., Akaike A. Excitotoxic degeneration of hypothalamic orexin neurons in slice culture. Neurobiol. Dis. 2004, 15:61-69.
15. Katsuki H., Kurosu S., Michinaga S., Hisatsune A., Isohama Y., Izumi Y., Kume T., Akaike A. Depolarizing stimuli cause persistent and selective loss of orexin in rat hypothalamic slice culture. Peptides 2010, 31:1131-1138.
16. Katzenschlager R., Lees A.J. Treatment of Parkinson's disease: Levodopa as the first choice. J. Neurol. 2002, 249:II19-II24.
17. Kessler B.A., Stanley E.M., Frederick-Duus D., Fadel J. Age-related loss of orexin/hypocretin neurons. Neuroscience 2011, 178:82-88.
18. Kilduff T.S., Peyron C. The hypocretin/orexin ligand-receptor system: Implications for sleep and sleep disorders. Trends Neurosci. 2000, 23:359-365.
19. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
20. Li Y., van den Pol A.N. Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. J. Neurosci. 2005, 25:173-183.
21. Li Y., Gao X.B., Sakurai T., van den Pol A.N. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 2002, 36:1169-1181.
22. Michinaga S., Hisatsune A., Isohama Y., Katsuki H. An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture. Neurosci. Res. 2010, 68:315-321.
23. Michinaga S., Hisatsune A., Isohama Y., Katsuki H. Inhibition of neural activity depletes orexin from rat hypothalamic slice culture. J. Neurosci. Res. 2010, 88:214-221.
24. Paus S., Brecht H.M., Köster J., Seeger G., Klockgether T., Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov. Disord. 2003, 18:659-667.
25. Petersén A., Gil J., Maat-Schieman M.L., Björkqvist M., Tanila H., Araújo I.M., Smith R., Popovic N., Wierup N., Norlén P., Li J.Y., Roos R.A., et al. Orexin loss in Huntington's disease. Hum. Mol. Genet. 2005, 14:39-47.
26. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000, 6:991-997.
27. Ravikumar K., Sridhar B. Ropinirole hydrochloride, a dopamine agonist. Acta Crystallogr. C 2006, 62:o265-o267.
28. Sakurai T. The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat. Rev. Neurosci. 2007, 8:171-181.
29. Sakurai T., Mieda M. Connectomics of orexin-producing neurons: Interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol. Sci. 2011, 32:451-462.
30. Steiger M., Jost W., Grandas F., Van Camp G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: A systematic review. J. Neural Transm. 2009, 116:179-191.
31. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
32. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
33. Tsujino N., Sakurai T. Orexin/hypocretin: A neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol. Rev. 2009, 61:162-176.
34. Wulff K., Gatti S., Wettstein J.G., Foster R.G. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat. Rev. Neurosci. 2010, 11:589-599.
35. Yamamoto Y., Ueta Y., Hara Y., Serino R., Nomura M., Shibuya I., Shirahata A., Yamashita H. Postnatal development of orexin/hypocretin in rats. Mol. Brain Res. 2000, 78:108-119.
36. Yamanaka A., Muraki Y., Ichiki K., Tsujino N., Kilduff T.S., Goto K., Sakurai T. Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. J. Neurophysiol. 2006, 96:284-298.
37. Zeitzer J.M., Nishino S., Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol. Sci. 2006, 27:368-374.